# Neo-adjuvant chemotherapy in fertility-sparing cervical cancer treatment.

**Tumor:** Ginecológico
**Autores:** Kasius JC
**Revista:** Best Pract Res Clin Obstet Gynaecol (2021)
**PMID:** 33752979 | **PMCID:** —
**DOI:** [10.1016/j.bpobgyn.2021.01.010](https://doi.org/10.1016/j.bpobgyn.2021.01.010)
**Fuente:** PubMed (abstract only)

## Relevancia
Cáncer ginecológico (cervix, vulva) tratado con quimioterapia neoadyuvante: pCR ganglionar pélvico/inguinal, downstaging y selección para cirugía preservadora de fertilidad o vulvectomía. Aporta paralelos con mama en la cirugía de menor extensión tras buena respuesta nodal a NAC.

## Abstract
The current review provides a literature overview of studies assessing the oncological and fertility outcomes of treatment with neo-adjuvant chemotherapy followed by fertility-sparing surgery in patients with cervical cancer >2 cm. Six cohort studies were included. In total, 111 patients were studied. Patients were on average 29 years old, had a tumor of 36 mm, no lymph node metastasis, and response to chemotherapy. In approximately 5-year follow-up, the recurrence rate was 13%, overall death rate 2.7%. Of the 111 patients, 90 underwent successful fertility-sparing treatment (83%).

## Acceso
Vía [DOI](https://doi.org/10.1016/j.bpobgyn.2021.01.010) o suscripción institucional.

---
*Datos de PubMed. Citar: doi 10.1016/j.bpobgyn.2021.01.010*
